LAVA Therapeutics (LVTX) News Today $1.26 -0.01 (-0.79%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC WainwrightApril 1 at 2:29 AM | americanbankingnews.comLava Therapeutics reports Q4 EPS (14c) vs. (24c) last yearMarch 29 at 3:23 AM | markets.businessinsider.comLAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99MMarch 28, 2025 | seekingalpha.comLAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 28, 2025 | globenewswire.comAnalyst Downgrades LAVA Therapeutics, Sees Pipeline OverhangFebruary 28, 2025 | benzinga.comCautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce ReductionFebruary 27, 2025 | tipranks.comLava Therapeutics announces evaluation of strategic optionsFebruary 26, 2025 | markets.businessinsider.comLAVA Therapeutics (NASDAQ:LVTX) Stock Quotes, Forecast and News SummaryFebruary 26, 2025 | benzinga.comLava Therapeutics trims workforce by 30% to preserve cashFebruary 25, 2025 | bizjournals.comLAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological CancersJanuary 10, 2025 | globenewswire.comLAVA Therapeutics to Transition to U.S. Domestic IssuerJanuary 2, 2025 | tipranks.comLeerink Partners Downgrades LAVA Therapeutics N.V. (LVTX)December 13, 2024 | msn.comJMP Securities downgrades LAVA Therapeutics (LVTX) to a HoldDecember 11, 2024 | markets.businessinsider.comLAVA Therapeutics Reports Increased Losses Amid Declining RevenuesDecember 10, 2024 | tipranks.comLAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027December 10, 2024 | globenewswire.com3 Healthcare Stocks Analysts Expect to Rally Over 50%September 25, 2024 | stocknews.comLAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comLAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Bolster Buy RatingAugust 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: LAVA Therapeutics’ Financial Stability and Promising Clinical PipelineAugust 21, 2024 | markets.businessinsider.comLAVA Reports Second Quarter 2024 Financial Results and Business UpdateAugust 20, 2024 | globenewswire.com4 Stocks Under $5 To Buy NowAugust 8, 2024 | 247wallst.comLAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 20, 2024 | globenewswire.comLAVA Announces Annual Meeting of ShareholdersJune 10, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 30, 2024 | globenewswire.comLAVA Therapeutics GAAP EPS of -$0.02 beats by $0.20, revenue of $6.99M beats by $3.49MMay 21, 2024 | seekingalpha.comLAVA Provides Business Updates and Reports First Quarter 2024 Financial ResultsMay 21, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Citizens JMP Life Sciences ConferenceMay 6, 2024 | globenewswire.comBuy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong FinancialsMarch 25, 2024 | markets.businessinsider.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 20, 2024 | finance.yahoo.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 20, 2024 | globenewswire.comLAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 6, 2024 | finanznachrichten.deLava gets $7M from Pfizer as trial for cancer drug advancesMarch 5, 2024 | msn.comLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 5, 2024 | globenewswire.comLAVA Therapeutics (NASDAQ:LVTX) Trading Up 37.7%LAVA Therapeutics (NASDAQ:LVTX) Trading 37.7% HigherMarch 5, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)March 1, 2024 | markets.businessinsider.comLAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest ReportFebruary 21, 2024 | benzinga.comLAVA Therapeutics NV (LVTX)February 14, 2024 | investing.comLava signs collaboration agreement with MSD for prostate cancer therapyJanuary 25, 2024 | msn.comPCSA, ONCO and KAVL among mid-day moversJanuary 25, 2024 | seekingalpha.comLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®January 25, 2024 | finance.yahoo.comLAVA Therapeutics N.V. (LVTX)December 13, 2023 | ca.finance.yahoo.comLAVA Therapeutics NV LVTXNovember 11, 2023 | morningstar.comLava Therapeutics is latest life sciences company to trim its workforceAugust 25, 2023 | bizjournals.comLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 22, 2023 | finanznachrichten.deLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 22, 2023 | finance.yahoo.comLAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34July 6, 2023 | msn.comLAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayJune 14, 2023 | finanznachrichten.deLava Therapeutics shelves hematology drug over competitive concernsJune 14, 2023 | msn.comHC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy RecommendationJune 12, 2023 | msn.comJMP Securities Remains a Buy on LAVA Therapeutics (LVTX)June 9, 2023 | markets.businessinsider.com Remove Ads Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address LVTX Media Mentions By Week LVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LVTX News Sentiment▼0.730.78▲Average Medical News Sentiment LVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LVTX Articles This Week▼80▲LVTX Articles Average Week Remove Ads Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Journey Medical News Eupraxia Pharmaceuticals News Alector News Lexeo Therapeutics News Telomir Pharmaceuticals News Genelux News Enanta Pharmaceuticals News Instil Bio News Sagimet Biosciences News Seres Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LVTX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
